Mankind Pharma Limited has informed the Exchange about Investor Presentation
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma shared its Q1 FY26 investor presentation alongside its quarterly results. Revenue grew 24.5% YoY to Rs 3,570 Cr, driven by strong domestic growth (up 19%) and a sharp 81% jump in exports on BSV consolidation. EBITDA rose 25.8% YoY to Rs 850 Cr with margins of 23.8%, up 150 bps sequentially. However, profit after tax fell 17.4% YoY to Rs 445 Cr due to higher depreciation and finance costs from the BSV acquisition, with PAT margins compressing 630 bps YoY to 12.5%. The company maintained its #1 prescription rank, gained market share to 4.9% (from 4.8%), and delivered 2.5% volume growth versus 1.4% for the industry. The Board declared an interim dividend of Rs 1 per share as Mankind marks 30 years of operations.
Mixed quarter for shareholders – top-line and operational metrics are strong, but bottom-line pressure from BSV integration costs may weigh on near-term sentiment. The interim dividend and improving market share provide some comfort, but watch margin trajectory and debt reduction (Net Debt/EBITDA at 1.6x).